Physician profile
Mohammad Emran
NPI 1811932999
$3,320.72
in general payments reported to CMS, 2019-2025
30 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $715 · 2021: $834 · 2022: $244 · 2023: $277 · 2024: $422 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $455.88 | 2019-2022 | |
| Astellas Pharma US INC | $331.69 | 2019-2023 | Veozah |
| Abbvie INC. | $316.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $292.56 | 2020-2025 | Farxiga |
| Lilly USA, LLC | $272.82 | 2020-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $231.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $218.16 | 2020-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $196.89 | 2019-2022 | |
| Novo Nordisk INC | $102.19 | 2019-2023 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $98.34 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $91.13 | 2020-2021 | |
| Pfizer INC. | $90.25 | 2019-2023 | |
| Ethicon US, LLC | $76.31 | 2025 | Enseal, Harmonic |
| Merck Sharp & Dohme LLC | $65.50 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.11 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $57.08 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $54.32 | 2024-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $50.30 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $38.47 | 2023-2025 | Gvoke Hypopen |
| Eisai INC. | $29.22 | 2021 | |
| Medicure Pharma INC. | $26.55 | 2019 | |
| Irhythm Technologies, INC. | $26.21 | 2021 | |
| Kyowa Kirin, INC. | $26.20 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.96 | 2023 | |
| Cvrx, INC. | $18.72 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $18.03 | 2019 | |
| Dexcom, INC. | $15.61 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $14.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.93 | 2021 | |
| Antares Pharma, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Emran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.